Tumour targeted polymer nanoparticles co-loaded with docetaxel and siCCAT2 for combination therapy of lung cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Prokop M. Lung cancer screening: the radiologist's perspective. Semin Respir Crit Care Med. 2014;35(1):91–98.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen Y, Sun X, et al. Prognostic roles of the expression of sphingosine-1-phosphate metabolism enzymes in non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(5):674–681.
   PubMed Web of Science ®Google Scholar
• Miura N, Kohno M, Ito K, et al. Lung cancer surgery in patients aged 80 years or older: an analysis of risk factors, morbidity, and mortality. Gen Thorac Cardiovasc Surg. 2015;63(7):401–405.
   PubMedGoogle Scholar
• Fan Y, Huang Z, Fang L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther. 2013;6:1789–1803.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Koinis F, Fallon MT, et al. Prognosis in advanced lung cancer–a prospective study examining key clinicopathological factors. Lung Cancer. 2015;88(3):304–309.
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Finn SP, et al. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev. 2015;41(2):160–169.
   PubMed Web of Science ®Google Scholar
• Gelvan A, Risum S, Langer SW. Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries. Dan Med J. 2015;62:A5033.
   PubMed Web of Science ®Google Scholar
• Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a Meta-analysis. Transl Lung Cancer Res. 2015;4(2):203–208.
   PubMedGoogle Scholar
• Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem. 2012;7(6):952–972.
   PubMed Web of Science ®Google Scholar
• Feng SQ, Wang GJ, Zhang JW, et al. Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis. Acta Pharmacol Sin. 2018;39(10):1670–1680.
   PubMed Web of Science ®Google Scholar
• Newell M, Goruk S, Mazurak V, et al. Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts. Breast Cancer Res Treat. 2019;177(2):357–367.
   PubMed Web of Science ®Google Scholar
• Madsen CV, Adimi P, Jakobsen A, et al. Cabazitaxel – a treatment option in recurrent platinum-resistant ovarian cancer. Anticancer Res. 2020;40(9):5255–5261.
   PubMed Web of Science ®Google Scholar
• Shekari N, Asghari F, Haghnavaz N, et al. Let-7a could serve as a biomarker for chemo-responsiveness to docetaxel in gastric cancer. Anticancer Agents Med Chem. 2019;19(3):304–309.
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Patel K, Chowdhury N, et al. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017;7(1):15824.
   PubMedGoogle Scholar
• Magadoux L, Isambert N, Plenchette S, et al. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer. Int J Oncol. 2014;45(3):919–928.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Rychlik B, Storm G, et al. Multidrug resistance: physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013;65(13–14):1852–1865.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–164.
   PubMed Web of Science ®Google Scholar
• Mohammad IS, He W, Yin L. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 2018;100:335–348.
   PubMed Web of Science ®Google Scholar
• Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “generally recognized as safe” (GRAS) nanopharmaceuticals: a review. Adv Drug Deliv Rev. 2013;65(13–14):1828–1851.
   PubMed Web of Science ®Google Scholar
• Schmid A, Wolfensberger A, Nemeth J, et al. Monotherapy versus combination therapy for multidrug-resistant gram-negative infections: systematic review and meta-analysis. Sci Rep. 2019;9(1):15290.
   PubMed Web of Science ®Google Scholar
• Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev. 2016;98:35–40.
   PubMed Web of Science ®Google Scholar
• Guo N, Gao C, Liu J, et al. Reversal of ovarian cancer multidrug resistance by a combination of LAH4-L1-siMDR1 nanocomplexes with chemotherapeutics. Mol Pharm. 2018;15(5):1853–1861.
   PubMedGoogle Scholar
• Wang D, Chen Z, Xu H, et al. Long noncoding RNA CCAT2 as a novel biomaker of metastasis and prognosis in human cancer: a meta-analysis. Oncotarget. 2017;8(43):75664–75674.
   PubMedGoogle Scholar
• Barros-Silva D, Lobo J, Guimarães-Teixeira C, et al. VIRMA-dependent N6-methyladenosine modifications regulate the expression of long non-coding RNAs CCAT1 and CCAT2 in prostate cancer. Cancers. 2020;12(4):771.
   Web of Science ®Google Scholar
• Wu ZJ, Li Y, Wu YZ, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(4):706–714.
   PubMed Web of Science ®Google Scholar
• Xin Y, Li Z, Zheng H, et al. CCAT2: a novel oncogenic long non-coding RNA in human cancers. Cell Prolif. 2017;50(3):e12342.
   Web of Science ®Google Scholar
• Gao P, Sun D, Guo H, et al. LncRNA CCAT2 promotes proliferation and suppresses apoptosis of colorectal cancer cells. J Buon. 2020;25(4):1840–1846.
   PubMed Web of Science ®Google Scholar
• Aghebati-Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235(3):1962–1972.
   PubMed Web of Science ®Google Scholar
• Citores L, Ferreras JM, Muñoz R, et al. Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l. Cancer Lett. 2002;184(1):29–35.
   PubMed Web of Science ®Google Scholar
• Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017;12:935–947.
   PubMed Web of Science ®Google Scholar
• Feng X, Jiang D, Kang T, et al. Tumor-homing and penetrating peptide-functionalized photosensitizer-conjugated PEG-PLA nanoparticles for chemo-photodynamic combination therapy of drug-resistant cancer. ACS Appl Mater Interfaces. 2016;8(28):17817–17832.
   PubMed Web of Science ®Google Scholar
• Jiang D, Gao X, Kang T, et al. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer. Nanoscale. 2016;8(5):3100–3118.
   PubMed Web of Science ®Google Scholar
• Pang Z, Gao H, Yu Y, et al. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjug Chem. 2011;22(6):1171–1180.
   PubMed Web of Science ®Google Scholar
• Rafiei P, Haddadi A. Pharmacokinetic consequences of PLGA nanoparticles in docetaxel drug delivery. Pharm Nanotechnol. 2017;5(1):3–23.
   PubMedGoogle Scholar
• Wu CP, Hsieh CH, Wu YS. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm. 2011;8(6):1996–2011.
   PubMedGoogle Scholar
• Cheng X, Fan K, Wang L, et al. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. Cell Death Dis. 2020;11(2):92.
   PubMed Web of Science ®Google Scholar
• Li S, Zhang W, Yin X, et al. Mouse ATP-Binding cassette (ABC) transporters conferring multi-drug resistance. Anticancer Agents Med Chem. 2015;15(4):423–432.
   PubMed Web of Science ®Google Scholar
• Limtrakul P, Chearwae W, Shukla S, et al. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007;296(1–2):85–95.
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–286.
   PubMedGoogle Scholar
• Ingenito F, Roscigno G, Affinito A, et al. The role of exo-miRNAs in cancer: a focus on therapeutic and diagnostic applications. IJMS. 2019;20(19):4687.
   Google Scholar
• Acunzo M, Romano G, Wernicke D, et al. MicroRNA and cancer-a brief overview. Adv Biol Regul. 2015;57:1–9.
   PubMedGoogle Scholar
• Andersen GB, Tost J. Circulating miRNAs as biomarker in cancer. Recent Results Cancer Res. 2020;215:277–298.
   PubMedGoogle Scholar
• Wu M, Wang G, Tian W, et al. MiRNA-based therapeutics for lung cancer. Curr Pharm Des. 2018;23(39):5989–5996.
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, Chi D, et al. Non-coding RNAs in IGF-1R signaling regulation: the underlying pathophysiological link between diabetes and cancer. Cells. 2019;8(12):1638.
   Web of Science ®Google Scholar
• Chen KC, Chen PH, Ho KH, Shih CM, et al. IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PLOS One. 2019;14(12):e0225913.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhang H, Guo X, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol. 2018;11(1):88.
   PubMedGoogle Scholar
• Song Y, Zhao Y, Ding X, et al. microRNA-532 suppresses the PI3K/Akt signaling pathway to inhibit colorectal cancer progression by directly targeting IGF-1R. Am J Cancer Res. 2018;8(3):435–449.
   PubMed Web of Science ®Google Scholar